SAN DIEGO, Oct. 19, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback